Sign in Subscribe
Pharmaceutical industry

NeXstar Pharmaceuticals Acquires Supragen, Inc. to Enhance Immunology Research Capabilities

Strategic Insights

— 1 min read

NeXstar Pharmaceuticals, Inc., a Boulder-based pharmaceutical company, announced its definitive agreement to acquire Supragen, Inc., a privately held biotechnology company specializing in therapeutics and vaccines for T-cell mediated diseases. The acquisition aims to strengthen NeXstar's research and development capabilities in immunology, infectious diseases, and oncology. Supragen's scientific staff, consisting of 24 employees, will remain in Lakewood, Colorado, initially, before moving to NeXstar's facilities in Boulder within 12 to 18 months. The acquisition values Supragen at approximately $11 million, with the issuance of 753,425 shares of NeXstar common stock.

Key Takeaways:

  • NeXstar Pharmaceuticals acquires Supragen, Inc. for approximately $11 million, with the issuance of 753,425 shares of NeXstar common stock.
  • The acquisition aims to enhance NeXstar's research and development capabilities in immunology, infectious diseases, and oncology.
  • Supragen's scientific staff, consisting of 24 employees, will remain in Lakewood, Colorado, initially, before moving to NeXstar's facilities in Boulder within 12 to 18 months.
  • Supragen's founders, Brian Kotzin, M.D., John Kappler, Ph.D., and Philippa Marrack, Ph.D., will become scientific consultants to NeXstar and will consult on all of NeXstar's immunology programs.
  • Kappler and Marrack are internationally recognized for their pioneering work in the field of immunology, including their discovery of T-cell receptors and superantigens.
  • Kotzin is a nationally recognized rheumatologist and expert on autoimmune diseases.
  • The acquisition is expected to close within two weeks.

Statistics:

  • The acquisition values Supragen at approximately $11 million.
  • NeXstar will issue 753,425 shares of common stock to complete the transaction.
  • Supragen's scientific staff consists of 24 employees.
  • The acquisition is expected to close within two weeks.
  • NeXstar's research expenses will increase slightly in the short term due to the addition of Supragen's personnel.

Sources:

  • "NeXstar Pharmaceuticals, Inc. Announces Acquisition of Supragen, Inc." (Business Wire, August 29, 1995)
  • Supragen, Inc. LinkedIn Page (no date)
  • NeXstar Pharmaceuticals, Inc. Website (no date)
  • National Jewish Center for Immunology and Respiratory Medicine (NJC) Website (no date)

Read more